Shares of Enzymotec Ltd (NASDAQ:ENZY) have earned an average recommendation of “Hold” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $11.75.

A number of analysts recently weighed in on ENZY shares. Zacks Investment Research raised shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Jefferies Group reissued a “hold” rating and issued a $11.50 target price on shares of Enzymotec in a research note on Thursday, October 19th. Wells Fargo & Co upped their target price on shares of Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research note on Monday, October 30th. Finally, BidaskClub cut shares of Enzymotec from a “hold” rating to a “sell” rating in a research note on Saturday.

Enzymotec (ENZY) traded up $0.03 during midday trading on Friday, reaching $11.88. 533,744 shares of the company were exchanged, compared to its average volume of 124,233. The company has a market capitalization of $278.21, a PE ratio of -43.98, a P/E/G ratio of 3.19 and a beta of 1.22. Enzymotec has a twelve month low of $6.30 and a twelve month high of $12.35.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC bought a new stake in Enzymotec in the second quarter valued at about $2,350,000. Osborn Williams & Donohoe LLC bought a new stake in Enzymotec in the third quarter valued at about $137,000. State Street Corp increased its stake in Enzymotec by 1.8% in the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 380 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in Enzymotec in the third quarter valued at about $107,000. 15.73% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/01/09/enzymotec-ltd-enzy-receives-11-75-consensus-pt-from-analysts.html.

About Enzymotec

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.